Increasing Screening Compliance for Colorectal Cancer, page-3

I'm not sure if I am an imbecile but can you please show me where this is written or paraphrased. It's blood based, it does not matter whether it is for mass population or not. It wasn't the point.

"The article states in the first paragraph that Guardant are keenly investing in possibly ways to raise compliance among test resistant people".

Again, please show me where it says this or it is paraphrased in the first paragraph that it is "to raise compliance among test resistant people".

Shield is commercially available for eligible individuals by prescription only through healthcare professionals. This LDT (Laboratory Developed Test) is intended to be complementary to, and not a replacement for, current recommended CRC screening methods. A negative result does not rule out the presence of cancer. Patients with an abnormal blood-based screening result should be referred for a diagnostic colonoscopic evaluation.

LOL